These are top 10 stocks traded on the Robinhood UK platform in July
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), sold 23,107 shares of Class A Common Stock on June 23, 2025, for approximately $1.09 million. The shares were sold at prices ranging from $47.15 to $47.43.
The sale was executed under a Rule 10b5-1 trading plan adopted on May 31, 2024. Following the transaction, Okupe directly owns 63,222 shares of Hims & Hers Health, Inc. Class A Common Stock. Okupe also indirectly owns 70,575 shares held by the Oluyemi Okupe Separate Property Trust dtd 9-1-2021.
In other recent news, Hims and Hers announced its acquisition of ZAVA, a European telemedicine platform, which is expected to expand its presence in Germany, France, and the UK. The company plans to complete the acquisition in the second half of 2025, anticipating accretive benefits by 2026. Needham analysts responded positively to this development, raising the stock price target to $65 and maintaining a Buy rating. Meanwhile, Morgan Stanley (NYSE:MS) and TD Cowen maintained their ratings at Equalweight and Hold, respectively, with price targets of $40 and $38.
In a separate development, Novo Nordisk (NYSE:NVO) terminated its partnership with Hims and Hers, citing concerns over the company’s promotion practices. This led Needham to downgrade Hims and Hers from Buy to Hold, noting potential legal and regulatory challenges. Morgan Stanley also highlighted slowing growth metrics, with app downloads showing a modest increase and web traffic growth below average. Analysts continue to monitor the impact of these developments on Hims and Hers’ business momentum and growth strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.